AANS Beyond 2021: Full Collection-Efficacy of Ulta-Microdose Intrathecal Morphine Delivery in the Treatment of Chronic Pain

Efficacy of Ulta-Microdose Intrathecal Morphine Delivery in the Treatment of Chronic Pain

Video Transcription

Video Summary

In this video presentation, Muhammad Jalal discusses the efficacy of ultramicrodose intrathecal morphine delivery in treating chronic pain. The study aimed to determine the effectiveness of delivering ultramicrodoses (less than 0.20 mg) of intrathecal morphine via an implanted drug delivery system. The methods involved enrolling patients and performing an outpatient intrathecal morphine trial. If a 60% reduction in pain was observed, a permanent intrathecal catheter and morphine pump were implanted. The drug delivery system then administered ultramicrodoses of morphine ranging from 0.065 mg to 0.195 mg over 24 hours. The safety and efficacy of the treatment were assessed, with positive results showing significant pain reduction without complications or infections. The presentation concludes by suggesting the need for a future multicenter study. No credits were mentioned in the video.

Keywords

ultramicrodose intrathecal morphine delivery

chronic pain treatment

implanted drug delivery system

intrathecal morphine trial

pain reduction